TW200500073A - Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof - Google Patents

Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof

Info

Publication number
TW200500073A
TW200500073A TW093103888A TW93103888A TW200500073A TW 200500073 A TW200500073 A TW 200500073A TW 093103888 A TW093103888 A TW 093103888A TW 93103888 A TW93103888 A TW 93103888A TW 200500073 A TW200500073 A TW 200500073A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
indolopyrrolocarbazole derivative
indolopyrrolocarbazole
derivative
edotecarin
Prior art date
Application number
TW093103888A
Other languages
Chinese (zh)
Inventor
Marina Ciomei
Enrico Pesenti
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of TW200500073A publication Critical patent/TW200500073A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to a method for treating cancer in a subject in need of such a treatment, said method comprising the administration to the patient of a therapeutically effective amount of edotecarin together with capecitabine or docetaxel.
TW093103888A 2003-02-21 2004-02-18 Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof TW200500073A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000317A ITMI20030317A1 (en) 2003-02-21 2003-02-21 COMBINED THERAPY INCLUDING AN INDOLOPIRROLOCARBAZOLO DERIVATIVE AND ANOTHER ANTI-CANCER AGENT.

Publications (1)

Publication Number Publication Date
TW200500073A true TW200500073A (en) 2005-01-01

Family

ID=32894164

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093103888A TW200500073A (en) 2003-02-21 2004-02-18 Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof

Country Status (10)

Country Link
EP (1) EP1599210A1 (en)
JP (1) JP2006518355A (en)
AR (1) AR043241A1 (en)
BR (1) BRPI0407642A (en)
CA (1) CA2516097A1 (en)
CL (1) CL2004000319A1 (en)
IT (1) ITMI20030317A1 (en)
MX (1) MXPA05008879A (en)
TW (1) TW200500073A (en)
WO (1) WO2004073719A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ575388A (en) * 2006-10-06 2012-03-30 Bn Immunotherapeutics Inc Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
SK12242002A3 (en) * 2000-02-28 2003-02-04 Aventis Pharma S. A. A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer

Also Published As

Publication number Publication date
CL2004000319A1 (en) 2005-04-22
ITMI20030317A1 (en) 2004-08-22
AR043241A1 (en) 2005-07-20
EP1599210A1 (en) 2005-11-30
CA2516097A1 (en) 2004-09-02
WO2004073719A1 (en) 2004-09-02
JP2006518355A (en) 2006-08-10
BRPI0407642A (en) 2006-03-01
MXPA05008879A (en) 2005-10-05

Similar Documents

Publication Publication Date Title
LUC00011I2 (en)
MXPA05013642A (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer.
TW200612987A (en) Combination treatment for non-hematologic malignancies
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
DK1169059T3 (en) Docetaxel in combination with rhuMAb HER2 for the treatment of cancers
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
IS6558A (en) Mixed disease treatment with vasoconstrictor
EP1503748A4 (en) Drugs for mitigating taxane-induced neurotoxicity
NO20064753L (en) combination therapy
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
BR0316010A (en) Combination
MXPA04009012A (en) Combination ofa cdk inhibitor and 5-fu for the treatment of cancer.
BRPI0409870A (en) use of irinotecan for treatment of resistant breast cancer
MXPA05013827A (en) Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer.
NO20051601L (en) Combination therapy with gemcitabine and zd6126